相关实验视频
Updated: Jun 24, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
68
在类风湿性关节炎中,介素-33的免疫调节作用:系统性审查
Renli Liu1, Fangfang Wang1, Xing Luo1
1Department of Clinical Immunology, Xijing Hospital, Air Force Medical University, 127 Changle West Road, Xi 'an City, Shaanxi Province 710032, China.
Clinical immunology (Orlando, Fla.)
|June 2, 2024
概括
介素-33 (IL-33) 促进了类风湿性关节炎 (RA) 的发展和进展. 准IL-33/ST2通路为RA提供了潜在的新疗法,解决炎症和耐药性.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 分子生物学分子生物学
背景情况:
- 类风湿性关节炎 (RA) 是一种由复杂的免疫细胞相互作用和炎症驱动的慢性自身免疫性疾病.
- 细胞因子风暴,特别是涉及Interleukin-33 (IL-33),在RA病变发生过程中越来越多地被认可.
- 通过其受体ST2作用的IL-33调节了参与RA的各种免疫细胞.
研究的目的:
- 阐明IL-33在类风湿性关节炎病理生理学和进展中的作用.
- 通过元分析分析IL-33水平与RA风险之间的关联.
- 探索针对IL-33/ST2途径治疗RA和药物耐药性的治疗潜力.
主要方法:
- 在RA中对IL-33的调节途径进行文献综述和分析.
- 在RA患者中检查血清和突液IL-33水平的研究的元分析.
- 调查IL-33和ST2参与RA中的免疫细胞调节.
- 对与IL-33和RA敏感性相关的遗传多态度的审查.
主要成果:
- IL-33显著促进了RA的发病和病理生理进展 (SMD=1.29).
- 在RA突体,血清和突液中检测到IL-33,这表明它参与其中.
- IL-33/ST2信号通路调节了关键的免疫细胞,这些免疫细胞与RA的发病有关.
- IL-33和相关的遗传因素可能在RA药物耐药性中发挥作用.
结论:
- IL-33是RA发病和进展的关键调解者.
- IL-33可以作为预测RA风险和治疗结果的生物标志物.
- 向IL-33/ST2通路为RA提供了一个有希望的治疗策略,可能克服耐药性.
相关概念视频
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
157
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
157
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Drugs Used in Lower Respiratory Disorders: Overview
420
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
420

